Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 477 Jan 1 – Oct 25, 2026
- Disclosed funding
- $20.2B 403 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| N Develops implant for treating articular cartilage defects in the knee | $4.1M | Seed2Seed | Biotech | United States | Investors | |
| V Provides intelligent software platforms for oncology care | $43M | Undisclosed | Biotech, Healthtech | United States | Investors | |
| MT Mirador TherapeuticsCompany profile Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases | $250M | Series B | Biotech | United States | Investors | |
| AA Allos AICompany profile Causal AI and pharmaceutical development services for reformulating complex drugs and directing laboratory studies. Causal AI and pharmaceutical development services for reformulating complex drugs and directing laboratory studies. | $5M | Seed | Biotech, AI | United States | Investors | |
| TB Trailhead BiosystemsCompany profile Develops human cells with defined molecular and functional properties for drug discovery and regenerative medicine Develops human cells with defined molecular and functional properties for drug discovery and regenerative medicine | $20M | Growth | Biotech | United States | Investors | |
| OT Oricell TherapeuticsCompany profile Develops next-generation cell therapies for oncology and immunology Develops next-generation cell therapies for oncology and immunology | $70M | Series C1Series C+ | Biotech | China | Investors | |
| JT Develops regenerative biologics to restore tissue function | $33.5M | Series B | Biotech | United States | Investors | |
| O Develops AI-based predictive genomics approach to target discovery | £2.5M | Seed | Biotech | United Kingdom | Investors | |
| KT Develops inhaled therapies for severe respiratory diseases | $103M | Series B | Biotech | United States | Investors | |
| M MEDIPOSTCompany profile MEDIPOST develops stem-cell therapies derived from donated umbilical cord blood. MEDIPOST develops stem-cell therapies derived from donated umbilical cord blood. | $140M | Undisclosed | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
23rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.